A recent survey of U.S. adults age 50 and older found that 31% had never been screened for colorectal cancer. The survey was conducted by the Colon Cancer Alliance and Quest Diagnostics. Colorectal cancer is the second leading cause of cancer death in... Continue Reading

Three separate studies have suggested that the benefit of Revlimid® (lenalidomide) for the initial treatment of patients with multiple myeloma outweighs the possible increased risk of developing secondary malignancies. These three studies were presented... Continue Reading

The chemotherapy regimen referred to as XELOX may improve overall survival compared with observation alone in stages II and III gastric (stomach) cancer; however, data are still immature and longer follow-up is necessary. These results were presented... Continue Reading

Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical Oncology (ASCO) meeting. Hepatocellular carcinoma... Continue Reading

For women with early-stage triple-negative breast cancer, treatment with breast-conserving surgery plus radiation therapy may result in fewer cancer recurrences in or near the breast than mastectomy without radiation therapy. These results were published... Continue Reading

In the most recent version of the National Toxicology Program’s Report on Carcinogens, two new substances have been classified as “known human carcinogens” and six others have been classified as “reasonably anticipated to be human carcinogens.” The... Continue Reading

Cancer survivors tend to pay substantially more in annual medical costs compared with people who have never had cancer. These findings were recently reported in Cancer. A significant number of adults in the United States are cancer survivors—approximately... Continue Reading

Researchers affiliated with the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) have reported that conventional chemoimmunotherapy was superior to sequential high-dose chemotherapy with autologous stem cell support for the treatment of high-risk... Continue Reading

The Phase III EMILIA trial is enrolling women with previously treated, HER2-positive, locally advanced or metastatic breast cancer. The study is evaluating an investigational drug known as trastuzumab emtansine (T-DM1). T-DM1 links the HER2-targeted... Continue Reading

Researchers involved in an international study have reported that a new tyrosine kinase inhibitor, bosutinib, appears to be superior to Gleevec® (imatinib) for the initial therapy of patients with chronic myeloid leukemia (CML). The early results of... Continue Reading

Among patients with relapsed multiple myeloma, treatment with the investigational drug elotuzumab plus Revlimid® (lenalidomide) and low-dose dexamethasone resulted in high response rates. The results of this Phase II clinical trial were presented at... Continue Reading

Researchers involved in an international multicenter trial have reported that brentuximab vedotin was effective for treatment of patients with relapsed or refractory anaplastic large cell lymphoma. The details of this study were reported at the 2011 meeting... Continue Reading